| Autor: |
Stephen A. Martin, Jordon Bosse, Amanda Wilson, Phyllis Losikoff, Lisa Chiodo |
| Jazyk: |
angličtina |
| Rok vydání: |
2018 |
| Předmět: |
|
| Zdroj: |
Addiction Science & Clinical Practice, Vol 13, Iss 1, Pp 1-4 (2018) |
| Druh dokumentu: |
article |
| ISSN: |
1940-0640 |
| DOI: |
10.1186/s13722-018-0111-7 |
| Popis: |
Abstract For over a decade, the vast majority of new hepatitis C virus (HCV) infections have been among young people who inject drugs (PWID). Well-characterized gaps in chronic HCV diagnosis, evaluation, and treatment have resulted in fewer than 5% of PWID receiving HCV treatment. While interferon-based treatment may have intentionally been foregone during part of this time in anticipation of improved oral therapies, the overall pattern points to deficiencies and treatment exclusions in the health care system. Treatment for HCV with all-oral, highly effective direct-acting antiviral medication for 12 weeks or less is now the standard of care, putting renewed focus on effective delivery of care. We describe here both the need for and process of chronic HCV care under the roof of addiction medicine. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Full text from SpringerLink